SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2002-12-3784. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-12-3784v1 102/3/1075    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kumar, S. Articles by Witzig, T. E. Search for Related Content PubMed PubMed Citation Articles by Kumar, S. Articles by Witzig, T. E. Related Collections Immunobiology Neoplasia Immunotherapy Brief Reports Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2003, Vol. 102, No. 3, pp. 1075-1077 NEOPLASIA Brief report Expression of CD52 on plasma cells in plasma cell proliferative disorders Shaji Kumar, Teresa K. Kimlinger, John A. Lust, Kathleen Donovan, and Thomas E. Witzig From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN Multiple myeloma (MM) and primary systemic amyloidosis (AL) remain incurable disorders, and new treatments targeted to the malignant plasma cells are needed. Alemtuzumab is a humanized monoclonal antibody to CD52 and has activity in chronic lymphocytic leukemia. We examined the CD52 expression on CD45+ and CD45- plasma cell populations to evaluate the potential for using alemtuzumab for these disorders. Bone marrows from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied using 3-color (CD38/45/52) flow cytometry. Among those with MGUS, MM, and AL, 67%, 52%, and 35%, respectively, were positive for CD52 expression. The CD52 expression was predominantly confined to the clonal CD38+/CD45+ plasma cell fraction with median expression of 68%, 88%, and 82% in MGUS, MM, and AL, respectively, compared with 18%, 6%, and 9% among the CD45- plasma cell population. Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The MoAb reloaded? Is alemtuzumab the one? Raymond L. Comenzo Blood 2003 102: 779. [Full Text] [PDF] This article has been cited by other articles: P. Zhou, R. L. Comenzo, A. B. Olshen, E. Bonvini, S. Koenig, P. G. Maslak, M. Fleisher, J. Hoffman, S. Jhanwar, J. W. Young, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy Blood, April 1, 2008; 111(7): 3403 - 3406. [Abstract] [Full Text] [PDF] M. S. Zand, T. Vo, T. Pellegrin, R. Felgar, J. L. Liesveld, J. J. Ifthikharuddin, C. N. Abboud, I. Sanz, and J. Huggins Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin Blood, April 1, 2006; 107(7): 2895 - 2903. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020